Department of Medical Oncology, Olivia-Newton John Cancer and Wellness Centre, Victoria, Australia.
Ludwig Institute for Cancer Research, Austin Health, Victoria, Australia ; Department of Pathology, University of Melbourne, Victoria, Australia ; School of Cancer Medicine, La Trobe University, Victoria, Australia.
Clin Epidemiol. 2014 Nov 20;6:423-32. doi: 10.2147/CLEP.S69718. eCollection 2014.
Improved understanding of molecular drivers of carcinogenesis has led to significant progress in the management of lung cancer. Patients with non-small-cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangements constitute about 4%-5% of all NSCLC patients. ALK+ NSCLC cells respond well to small molecule ALK inhibitors such as crizotinib; however, resistance invariably develops after several months of treatment. There are now several newer ALK inhibitors, with the next generation of agents targeting resistance mutations. In this review, we will discuss the prevalence and clinical characteristics of ALK+ lung cancer, current treatment options, and future directions in the management of this subset of NSCLC patients.
对致癌分子驱动因素的深入了解，推动了肺癌治疗的显著进展。具有间变性淋巴瘤激酶（ALK）基因重排的非小细胞肺癌（NSCLC）患者约占所有 NSCLC 患者的 4%-5%。ALK+ NSCLC 细胞对小分子 ALK 抑制剂如克唑替尼反应良好；然而，在治疗数月后，耐药性不可避免地会出现。目前有几种新型的 ALK 抑制剂，下一代药物针对耐药性突变。在这篇综述中，我们将讨论 ALK+肺癌的流行情况和临床特征、目前的治疗选择，以及这部分 NSCLC 患者管理的未来方向。
